|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM121151786 |
| 003 |
DE-627 |
| 005 |
20231222192433.0 |
| 007 |
tu |
| 008 |
231222s1993 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0404.xml
|
| 035 |
|
|
|a (DE-627)NLM121151786
|
| 035 |
|
|
|a (NLM)12286473
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a RU 486
|b an overview of mifepristone and its potential applications
|
| 264 |
|
1 |
|c 1993
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 01.12.1993
|
| 500 |
|
|
|a Date Revised 21.11.2013
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Abortifacient Agents
|
| 650 |
|
4 |
|a Abortion, Drug Induced
|
| 650 |
|
4 |
|a Abortion, Induced
|
| 650 |
|
4 |
|a Americas
|
| 650 |
|
4 |
|a Biology
|
| 650 |
|
4 |
|a Breast Cancer
|
| 650 |
|
4 |
|a Cancer
|
| 650 |
|
4 |
|a Cervical Dilatation
|
| 650 |
|
4 |
|a Contraception
|
| 650 |
|
4 |
|a Contraceptive Agents
|
| 650 |
|
4 |
|a Contraceptive Agents, Female
|
| 650 |
|
4 |
|a Contraceptive Agents, Postcoital
|
| 650 |
|
4 |
|a Contraceptive Mode Of Action
|
| 650 |
|
4 |
|a Developed Countries
|
| 650 |
|
4 |
|a Diseases
|
| 650 |
|
4 |
|a Endocrine System
|
| 650 |
|
4 |
|a Endometrial Effects
|
| 650 |
|
4 |
|a Endometrium
|
| 650 |
|
4 |
|a Europe
|
| 650 |
|
4 |
|a Family Planning
|
| 650 |
|
4 |
|a Fertility Control, Postcoital
|
| 650 |
|
4 |
|a Fertility Control, Postconception
|
| 650 |
|
4 |
|a France
|
| 650 |
|
4 |
|a Genitalia
|
| 650 |
|
4 |
|a Genitalia, Female
|
| 650 |
|
4 |
|a Hormone Antagonists
|
| 650 |
|
4 |
|a Hormones
|
| 650 |
|
4 |
|a Implantation Suppression
|
| 650 |
|
4 |
|a Literature Review
|
| 650 |
|
4 |
|a Mediterranean Countries
|
| 650 |
|
4 |
|a Menstrual Regulation
|
| 650 |
|
4 |
|a Neoplasms
|
| 650 |
|
4 |
|a North America
|
| 650 |
|
4 |
|a Northern America
|
| 650 |
|
4 |
|a Ovulation Suppression
|
| 650 |
|
4 |
|a Physiology
|
| 650 |
|
4 |
|a Ru-486--side effects
|
| 650 |
|
4 |
|a Treatment
|
| 650 |
|
4 |
|a United States
|
| 650 |
|
4 |
|a Urogenital System
|
| 650 |
|
4 |
|a Uterus
|
| 650 |
|
4 |
|a Western Europe
|
| 650 |
|
7 |
|a Abortifacient Agents
|2 NLM
|
| 650 |
|
7 |
|a Contraceptive Agents
|2 NLM
|
| 650 |
|
7 |
|a Contraceptive Agents, Female
|2 NLM
|
| 650 |
|
7 |
|a Contraceptives, Postcoital
|2 NLM
|
| 650 |
|
7 |
|a Hormone Antagonists
|2 NLM
|
| 650 |
|
7 |
|a Hormones
|2 NLM
|
| 650 |
|
7 |
|a Mifepristone
|2 NLM
|
| 650 |
|
7 |
|a 320T6RNW1F
|2 NLM
|
| 773 |
0 |
8 |
|i Enthalten in
|t Contraception Report
|d 1993
|g 4(1993), 2 vom: 28. Mai, Seite 7-9
|w (DE-627)NLM09824602X
|7 nnns
|
| 773 |
1 |
8 |
|g volume:4
|g year:1993
|g number:2
|g day:28
|g month:05
|g pages:7-9
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 4
|j 1993
|e 2
|b 28
|c 05
|h 7-9
|